Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

675 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Change in prognostic factors.
Hoelzer D, Gökbuget N. Hoelzer D, et al. Leuk Suppl. 2012 Aug;1(Suppl 2):S1-2. doi: 10.1038/leusup.2012.4. Epub 2012 Aug 9. Leuk Suppl. 2012. PMID: 27175230 Free PMC article.
Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia.
Pfeifer H, Wassmann B, Bethge W, Dengler J, Bornhäuser M, Stadler M, Beelen D, Vucinic V, Burmeister T, Stelljes M, Faul C, Dreger P, Kiani A, Schäfer-Eckart K, Schwerdtfeger R, Lange E, Kubuschok B, Horst HA, Gramatzki M, Brück P, Serve H, Hoelzer D, Gökbuget N, Ottmann OG; GMALL Study Group. Pfeifer H, et al. Among authors: hoelzer d. Leukemia. 2013 Jun;27(6):1254-62. doi: 10.1038/leu.2012.352. Epub 2012 Dec 5. Leukemia. 2013. PMID: 23212150 Clinical Trial.
Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib.
Wassmann B, Pfeifer H, Scheuring UJ, Binckebanck A, Gökbuget N, Atta J, Brück P, Rieder H, Schoch C, Leimer L, Schwerdtfeger R, Ehninger G, Lipp T, Perz J, Stelljes M, Gschaidmeier H, Hoelzer D, Ottmann OG. Wassmann B, et al. Among authors: hoelzer d. Blood. 2004 Feb 15;103(4):1495-8. doi: 10.1182/blood-2003-01-0154. Epub 2003 Oct 23. Blood. 2004. PMID: 14576058 Free article. Clinical Trial.
Treatment of adult acute lymphoblastic leukemia.
Gökbuget N, Hoelzer D. Gökbuget N, et al. Among authors: hoelzer d. Hematology Am Soc Hematol Educ Program. 2006:133-41. doi: 10.1182/asheducation-2006.1.133. Hematology Am Soc Hematol Educ Program. 2006. PMID: 17124052 Review.
Treatment of adult acute lymphoblastic leukemia.
Gökbuget N, Hoelzer D. Gökbuget N, et al. Among authors: hoelzer d. Semin Hematol. 2009 Jan;46(1):64-75. doi: 10.1053/j.seminhematol.2008.09.003. Semin Hematol. 2009. PMID: 19100369 Review.
Liposomal cytarabine is effective and tolerable in the treatment of central nervous system relapse of acute lymphoblastic leukemia and very aggressive lymphoma.
Gökbuget N, Hartog CM, Bassan R, Derigs HG, Dombret H, Greil R, Hernández-Rivas JM, Huguet F, Intermesoli T, Jourdan E, Junghanss C, Leimer L, Moreno MJ, Reichle A, Ribera J, Schmid M, Serve H, Stelljes M, Stuhlmann R, Hoelzer D; German Multicenter Study Group for Adult ALL and the European Working Group for Adult ALL. Gökbuget N, et al. Among authors: hoelzer d. Haematologica. 2011 Feb;96(2):238-44. doi: 10.3324/haematol.2010.028092. Epub 2010 Oct 15. Haematologica. 2011. PMID: 20952517 Free PMC article. Clinical Trial.
675 results